Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines
- PMID: 31456763
- PMCID: PMC6700363
- DOI: 10.3389/fmicb.2019.01796
Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines
Abstract
"Heteroresistance" is a widely applied term that characterizes most of the multidrug-resistant microorganisms. In microbiological practice, the word "heteroresistance" indicates diverse responses to specific antibiotics by bacterial subpopulations in the same patient. These resistant subpopulations of heteroresistant strains do not respond to antibiotic therapy in vitro or in vivo. Presently, there is no standard protocol available for the treatment of infections caused by heteroresistant Helicobacter pylori in clinical settings, at least according to recent guidelines. Thus, there is a definite need to open a new discussion on how to recognize, how to screen, and how to eliminate those problematic strains in clinical and environmental samples. Since there is great interest in developing new strategies to improve the eradication rate of anti-H. pylori treatments, the presence of heteroresistant strains/clones among clinical isolates of the bacteria should be taken into account. Indeed, increased knowledge of gastroenterologists about the existence of heteroresistance phenomena is highly required. Moreover, the accurate breakpoints should be examined/determined in order to have a solid statement of heteroresistance among the H. pylori isolates. The primary definition of heteroresistance was about coexistence of both resistant and susceptible isolates at the similar gastric microniche at once, while we think that it can be happened subsequently as well. The new guidelines should include a personalized aspect in the standard protocol to select a precise, effective antibiotic therapy for infected patients and also address the problems of regional antibiotic susceptibility profiles.
Keywords: Helicobacter pylori; antibiotic resistance; antibiotic therapy; guidelines; heteroresistance.
Similar articles
-
Heteroresistance of Helicobacter pylori from the same patient prior to antibiotic treatment.Infect Genet Evol. 2014 Apr;23:196-202. doi: 10.1016/j.meegid.2014.02.009. Epub 2014 Feb 24. Infect Genet Evol. 2014. PMID: 24576534
-
Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept.Helicobacter. 2020 Feb;25(1):e12670. doi: 10.1111/hel.12670. Epub 2019 Nov 8. Helicobacter. 2020. PMID: 31701608
-
Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.Helicobacter. 2023 Oct;28(5):e13006. doi: 10.1111/hel.13006. Epub 2023 Jul 4. Helicobacter. 2023. PMID: 37402147
-
Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection.Drug Des Devel Ther. 2017 Jul 28;11:2209-2220. doi: 10.2147/DDDT.S136240. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28814829 Free PMC article. Review.
-
Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2022 May 20;21(1):19. doi: 10.1186/s12941-022-00509-3. Ann Clin Microbiol Antimicrob. 2022. PMID: 35596211 Free PMC article. Review.
Cited by
-
Novel in vitro and in vivo anti-Helicobacter pylori effects of pomegranate peel ethanol extract.Vet World. 2021 Jan;14(1):120-128. doi: 10.14202/vetworld.2021.120-128. Epub 2021 Jan 16. Vet World. 2021. PMID: 33642795 Free PMC article.
-
Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments.Gut Liver. 2023 Sep 15;17(5):684-697. doi: 10.5009/gnl220429. Epub 2023 Feb 27. Gut Liver. 2023. PMID: 36843419 Free PMC article. Review.
-
Next-Generation Sequencing of the Whole Bacterial Genome for Tracking Molecular Insight into the Broad-Spectrum Antimicrobial Resistance of Helicobacter pylori Clinical Isolates from the Democratic Republic of Congo.Microorganisms. 2020 Jun 11;8(6):887. doi: 10.3390/microorganisms8060887. Microorganisms. 2020. PMID: 32545318 Free PMC article.
-
A Mini-review on Helicobacter pylori with Gastric Cancer and Available Treatments.Endocr Metab Immune Disord Drug Targets. 2024;24(3):277-290. doi: 10.2174/1871530323666230824161901. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 37622707 Review.
-
Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study.Pathol Oncol Res. 2021 Jun 29;27:1609863. doi: 10.3389/pore.2021.1609863. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34267605 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources